{"id":5910,"date":"2009-10-05T06:57:45","date_gmt":"2009-10-05T05:57:45","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5910"},"modified":"2013-08-16T10:28:14","modified_gmt":"2013-08-16T10:28:14","slug":"50mg-and-100mg-ritonavir-doses-achieve-similar-levels-of-saquinavir-in-thai-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5910","title":{"rendered":"50mg and 100mg ritonavir doses achieve similar levels of saquinavir in Thai patients"},"content":{"rendered":"<p><a href=\"http:\/\/www.hiv-druginteractions.org\">hiv-druginteractions.org<\/a><\/p>\n<p><strong>There has long been interest in the possibility of reducing the boosting dose of ritonavir from 100 mg to 50 mg. If the boosted PI exposure remains comparable with a lower dose ritonavir, then there will be potential toxicity benefit as well as economic benefit.<\/strong><\/p>\n<p>This was a PK study conducted in 20 HIV-infected Thai patients stable for at least 3 months on a regimen containing saquinavir\/ritonavir (1500\/100 mg once daily) plus 2 NRTI with a viral load &lt;50 copies\/ml. A 24-hour PK profile was initially obtained when patients were on 1500\/100 mg and then subsequently after 7 days on a reduced ritonavir dose (i.e. 1500\/50 mg once daily, ritonavir in liquid formulation). There was no difference in saquinavir PK parameters between the 2 PK days, whereas exposure to ritonavir was significantly reduced due to the dose reduction. The short-term reduction in ritonavir did not show a toxicity benefit.<\/p>\n<h3>Comment<\/h3>\n<p><strong>These data are important and highlight the need for a 50 mg ritonavir tablet or capsule rather than the liquid formulation. Additional studies in other patient populations would clearly add weight to the dose reduction strategy.<\/strong><\/p>\n<p>Source: <a href=\"http:\/\/www.hiv-druginteractions.org\">www.hiv-druginteractions.org<\/a><\/p>\n<p>Reference:<\/p>\n<p>Van der Lugt J et al. Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. AIDS, 2009, 23(9): 1176-1178.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>hiv-druginteractions.org There has long been interest in the possibility of reducing the boosting dose of ritonavir from 100 mg to 50 mg. If the boosted PI exposure remains comparable with a lower dose ritonavir, then there will be potential toxicity &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5910","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5910"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5910\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}